CCI: Polymer-free dual DES shows promise in first-in-human trial

07/30/2013 | Healio

In a feasibility trial of a polymer-free dual drug-eluting stent, Beijing researchers found no deaths, MI or stent thrombosis four months post-procedure and only three target lesion failure events linked to repeat revascularization at 18 months. In the study, reported in Catheterization and Cardiovascular Interventions, researchers placed the Bicare stent, a polymer-free nanotechnology stent that releases sirolimus and probucol, in 32 patients with a single de novo native coronary stenosis.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX